Melanoma: A model for testing new agents in combination therapies

por Ascierto, Paolo A, Streicher, Howard Z, Sznol, Mario
Publicado 2010

Immune checkpoint inhibitors in clinical trials

por Sharon, Elad, Streicher, Howard, Goncalves, Priscila, Chen, Helen X.
Publicado 2014

Ocular adverse events in PD-1 and PD-L1 inhibitors

por Young, LeAnne, Finnigan, Shanda, Streicher, Howard, Chen, Helen X, Murray, James, Sen, H Nida, Sharon, Elad
Publicado 2021

Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti–PD1/PDL1 Clinical Trials

por Reuss, Joshua E., Stern, Diana, Foster, Jared C., Ramaswami, Ramya, Lurain, Kathryn, Chen, Helen X., Streicher, Howard, Kem, Ravie, Little, Richard F., Sharon, Elad
Publicado 2020

Validation of biomarkers to predict response to immunotherapy in cancer: Volume II — clinical validation and regulatory considerations

por Dobbin, Kevin K., Cesano, Alessandra, Alvarez, John, Hawtin, Rachael, Janetzki, Sylvia, Kirsch, Ilan, Masucci, Giuseppe V., Robbins, Paul B., Selvan, Senthamil R., Streicher, Howard Z., Zhang, Jenny, Butterfield, Lisa H., Thurin, Magdalena
Publicado 2016

Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation

por Masucci, Giuseppe V., Cesano, Alessandra, Hawtin, Rachael, Janetzki, Sylvia, Zhang, Jenny, Kirsch, Ilan, Dobbin, Kevin K., Alvarez, John, Robbins, Paul B., Selvan, Senthamil R., Streicher, Howard Z., Butterfield, Lisa H., Thurin, Magdalena
Publicado 2016

Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors

por Rahma, Osama E, Tyan, Kevin, Giobbie-Hurder, Anita, Brohl, Andrew S, Bedard, Philippe L, Renouf, Daniel J, Sharon, Elad, Streicher, Howard, Hathaway, Emma, Cunningham, Rachel, Manos, Michael, Severgnini, Mariano, Rodig, Scott, Stephen Hodi, F
Publicado 2022

A phase I study of indoximod in patients with advanced malignancies

por Soliman, Hatem H., Minton, Susan E., Han, Hyo Sook, Ismail-Khan, Roohi, Neuger, Anthony, Khambati, Fatema, Noyes, David, Lush, Richard, Chiappori, Alberto A., Roberts, John D., Link, Charles, Vahanian, Nicholas N., Mautino, Mario, Streicher, Howard, Sullivan, Daniel M., Antonia, Scott J.
Publicado 2016

Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary

por Tarhini, Ahmad A, Lee, Sandra J, Tan, Aik-Choon, El Naqa, Issam M, Stephen Hodi, F, Butterfield, Lisa H, LaFramboise, William A, Storkus, Walter J, Karunamurthy, Arivarasan D, Conejo-Garcia, Jose R, Hwu, Patrick, Streicher, Howard, Sondak, Vernon K, Kirkwood, John M
Publicado 2022

Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to ma...

por Saad, Mariam, Lee, Sandra J., Tan, Aik Choon, El Naqa, Issam M., Hodi, F. Stephen, Butterfield, Lisa H., LaFramboise, William A., Storkus, Walter, Karunamurthy, Arivarasan D., Conejo-Garcia, Jose, Hwu, Patrick, Streicher, Howard, Sondak, Vernon K., Kirkwood, John M., Tarhini, Ahmad A.
Publicado 2022

Phase I Neoadjuvant Study of Intravesical Recombinant Fowlpox-GM-CSF (rF-GMCSF) or Fowlpox-TRICOM (rF-TRICOM) in Patients with Bladder Carcinoma

por Portal, Daniella E., Weiss, Robert E., Wojtowicz, Malgorzata, Mansour, Amal, Monken, Claude, Mehnert, Janice M., Aisner, Joseph A., Kane, Michael, Nishioka, Jennifer, Aisner, Seena, Peters, Stephen, Stein, Mark N., Kim, Isaac Y., Mayer, Tina M., Shih, Weichung, Gulley, James, Streicher, Howard, Singer, Eric A., Lattime, Edmund C.
Publicado 2019

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in...

por Wagner, Michael J, Othus, Megan, Patel, Sandip P, Ryan, Chris, Sangal, Ashish, Powers, Benjamin, Budd, G Thomas, Victor, Adrienne I, Hsueh, Chung-Tsen, Chugh, Rashmi, Nair, Suresh, Leu, Kirsten M, Agulnik, Mark, Sharon, Elad, Mayerson, Edward, Plets, Melissa, Blanke, Charles, Streicher, Howard, Chae, Young Kwang, Kurzrock, Razelle
Publicado 2021

Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas

por O'Sullivan Coyne, Geraldine, Kummar, Shivaani, Hu, James, Ganjoo, Kristen, Chow, Warren A., Do, Khanh T., Zlott, Jennifer, Bruns, Ashley, Rubinstein, Lawrence, Foster, Jared C., Juwara, Lamin, Meehan, Robert, Piekarz, Richard, Streicher, Howard, Sharon, Elad, Takebe, Naoko, Voth, Andrea Regier, Bottaro, Donald, Costello, Rene, Wright, John J., Doroshow, James H., Chen, Alice P.
Publicado 2022

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

por Tarhini, Ahmad A, Kang, Ni, Lee, Sandra J, Hodi, F Stephen, Cohen, Gary I, Hamid, Omid, Hutchins, Laura F, Sosman, Jeffrey A, Kluger, Harriet M, Eroglu, Zeynep, Koon, Henry B, Lawrence, Donald P, Kendra, Kari L, Minor, David R, Lee, Carrie B, Albertini, Mark R, Flaherty, Lawrence E, Petrella, Teresa M, Streicher, Howard, Sondak, Vernon K, Kirkwood, John M
Publicado 2021

Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas

por Coyne, Geraldine O'Sullivan, Kummar, Shivaani, Meehan, Robert S., Do, Khanh, Collins, Jerry M., Anderson, Larry, Ishii, Kazusa, Takebe, Naoko, Zlott, Jennifer, Juwara, Lamin, Piekarz, Richard, Streicher, Howard, Sharon, Elad, Rubinstein, Larry, Voth, Andrea Regier, Lozier, Jay, Dull, Angie B., Wilsker, Deborah, Hinoue, Toshinori, Laird, Peter W., Ferry-Galow, Katherine V., Kinders, Robert J., Parchment, Ralph E., Doroshow, James H., Chen, Alice P.
Publicado 2020

Phase 1 study of Z-endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors

por Takebe, Naoko, Coyne, Geraldine O'Sullivan, Kummar, Shivaani, Collins, Jerry, Reid, Joel M., Piekarz, Richard, Moore, Nancy, Juwara, Lamin, Johnson, Barry C., Bishop, Rachel, Lin, Frank I., Mena, Esther, Choyke, Peter L., Lindenberg, M. Liza, Rubinstein, Larry V., Bonilla, Cecilia Monge, Goetz, Matthew P., Ames, Matthew M., McGovern, Renee M., Streicher, Howard, Covey, Joseph M., Doroshow, James H., Chen, Alice P.
Publicado 2021

Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting

por Stroncek, David F, Melief, Cornelis JM, Castiello, Luciano, Cesano, Alessandra, Cheever, Martin A, Civini, Sara, Comin-Anduix, Begonya, Gajewski, Thomas F, Greenberg, Philip D, Kalinski, Pawel, Kaufman, Howard L, Kershaw, Michael H, Khleif, Samir N, Marincola, Francesco, Merritt, William, Munn, David H, Powell, Daniel J, Restifo, Nicholas P, Rosenberg, Steven A, Puri, Raj K, Streicher, Howard, Szalay, Aladar A, Yee, Cassian, Zitvogel, Laurence, Ribas, Antoni
Publicado 2013

A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"

por Butterfield, Lisa H, Disis, Mary L, Fox, Bernard A, Lee, Peter P, Khleif, Samir N, Thurin, Magdalena, Trinchieri, Giorgio, Wang, Ena, Wigginton, Jon, Chaussabel, Damien, Coukos, George, Dhodapkar, Madhav, Håkansson, Leif, Janetzki, Sylvia, Kleen, Thomas O, Kirkwood, John M, Maccalli, Cristina, Maecker, Holden, Maio, Michele, Malyguine, Anatoli, Masucci, Giuseppe, Palucka, A Karolina, Potter, Douglas M, Ribas, Antoni, Rivoltini, Licia, Schendel, Dolores, Seliger, Barbara, Selvan, Senthamil, Slingluff, Craig L, Stroncek, David F, Streicher, Howard, Wu, Xifeng, Zeskind, Benjamin, Zhao, Yingdong, Zocca, Mai-Britt, Zwierzina, Heinz, Marincola, Francesco M
Publicado 2008

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation

por Penter, Livius, Zhang, Yi, Savell, Alexandra, Huang, Teddy, Cieri, Nicoletta, Thrash, Emily M., Kim-Schulze, Seunghee, Jhaveri, Aashna, Fu, Jingxin, Ranasinghe, Srinika, Li, Shuqiang, Zhang, Wandi, Hathaway, Emma S., Nazzaro, Matthew, Kim, Haesook T., Chen, Helen, Thurin, Magdalena, Rodig, Scott J., Severgnini, Mariano, Cibulskis, Carrie, Gabriel, Stacey, Livak, Kenneth J., Cutler, Corey, Antin, Joseph H., Nikiforow, Sarah, Koreth, John, Ho, Vincent T., Armand, Philippe, Ritz, Jerome, Streicher, Howard, Neuberg, Donna, Hodi, F. Stephen, Gnjatic, Sacha, Soiffer, Robert J., Liu, X. Shirley, Davids, Matthew S., Bachireddy, Pavan, Wu, Catherine J.
Publicado 2021

Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

por Girardi, Daniel M., Niglio, Scot A., Mortazavi, Amir, Nadal, Rosa, Lara, Primo, Pal, Sumanta K., Saraiya, Biren, Cordes, Lisa, Ley, Lisa, Ortiz, Olena Sierra, Cadena, Jacqueline, Diaz, Carlos, Bagheri, Hadi, Redd, Bernadette, Steinberg, Seth M., Costello, Rene, Chan, Keith S., Lee, Min-Jung, Lee, Sunmin, Yu, Yunkai, Gurram, Sandeep, Chalfin, Heather J., Valera, Vladimir, Figg, William D., Merino, Maria, Toubaji, Antoun, Streicher, Howard, Wright, John J., Sharon, Elad, Parnes, Howard L., Ning, Yang-Min, Bottaro, Donald P., Cao, Liang, Trepel, Jane B., Apolo, Andrea B.
Publicado 2022